Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kiniksa Pharmaceuticals International (KNSA) Leases (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Leases readings, the most recent being $9.3 million for Q1 2026.

  • On a quarterly basis, Leases fell 10.71% to $9.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.3 million, a 10.71% decrease, with the full-year FY2025 number at $9.8 million, down 5.48% from a year prior.
  • Leases hit $9.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $9.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $13.2 million in Q2 2023 to a low of $4.1 million in Q2 2022.
  • Median Leases over the past 5 years was $10.3 million (2025), compared with a mean of $9.4 million.
  • Biggest five-year swings in Leases: dropped 24.45% in 2022 and later skyrocketed 224.18% in 2023.
  • Kiniksa Pharmaceuticals International's Leases stood at $5.4 million in 2022, then soared by 121.56% to $11.9 million in 2023, then dropped by 13.03% to $10.4 million in 2024, then dropped by 5.48% to $9.8 million in 2025, then fell by 4.82% to $9.3 million in 2026.
  • The last three reported values for Leases were $9.3 million (Q1 2026), $9.8 million (Q4 2025), and $10.1 million (Q3 2025) per Business Quant data.